^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Leiomyosarcoma
    Drug:Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    YONDELIS is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Trabectedin is included for palliative therapy as a category 1 recommendation for LPS and LMS (L-type) and as category 2A for non-L-type sarcomas...